Thymoma-Related Stiff-Person Syndrome with Successfully Treated by Surgery

Akihiro Sasaki, MD,1,2 Tatsuya Kato, MD, PhD,2 Hideki Ujiie, MD, PhD,2
Satoru Wakasa, MD, PhD,2 Setsuyuki Otake, MD, PhD,1 Keisuke Kikuchi, MD, PhD,3
and Koichi Ohno, MD, PhD1

Introduction: Stiff-person syndrome (SPS) is a rare autoimmune neurological disorder. Paraneoplastic SPS associated with malignant tumors such as thymoma occurs in approximately 5% of all SPS cases. We present a rare case of thymoma accompanied by SPS successfully treated using surgery.

Presentation of Case: A 26-year-old woman presented with lower limbs convulsions and gait disturbance and complained of leg pain. Cerebrospinal fluid and blood test results showed a high level of anti-glutamic acid decarboxylase (GAD) antibodies. Computed tomography showed anterior mediastinal tumor suggestive of a thymoma. She underwent extended thymectomy, and her symptoms gradually improved after surgery. No evidence of recurrent thymoma and SPS has been observed over 44 months.

Conclusion: Surgical treatment would be effective for patients with SPS and thymoma.

Keywords: stiff-person syndrome, paraneoplastic stiff-person syndrome, thymoma, anti-acetylcholine receptor antibody, myasthenia gravis
administered as symptomatic treatment were highly effective. A high level of anti-GAD antibody was detected in the cerebrospinal fluid and blood samples, and anti-acetylcholine receptor (AchR) antibody was slightly positive on the blood test. Brain–spine magnetic resonance imaging (MRI) showed no abnormalities. She was diagnosed with SPS, but she has not developed myasthenia gravis (MG). After the patient was treated with steroid pulse therapy and high-dose immunoglobulin therapy, these treatments relieved the clinical symptoms. Chest computed tomography showed anterior mediastinal tumor suspected as thymoma (Fig. 1A). MRI revealed that the mass was adjacent to the pericardium and lung, but no obvious invasion was detected (Fig. 1B and 1C). Paraneoplastic SPS associated with thymoma was suspected, and extended thymectomy was performed.

Macroscopically, a 4.8-cm clear grayish nodule in the right upper pole of the thymus was observed. Although the nodule was covered with a thick fibrous cap, there was a partial invasion into the surrounding thymic fat (Fig. 2A; white arrow). Microscopically, unclear boundaries of epithelial cells proliferating in the form of a sheet were observed and hematoxylin and eosin staining showed invasion of focal lymphocytes (Fig. 2B). Immunohistochemically, the tumor cells were positive for the expression of AE1/AE3 (Fig. 2C) and slightly positive for the expressions of CD3 and CD20 (Fig 2D and E); therefore, Type B3 thymoma (pathological stage II Masaoka classification) was diagnosed.

The postoperative course was uneventful. Anti-GAD antibody titer remained high (titer >2000). Anti-AchR antibody was slightly positive on the postoperative blood test, but she had no recurrence of neurological symptoms and did not develop MG. No evidence of recurrence of SPS and thymoma has been observed over 44 months.

Discussion

We experienced a rare case of extended thymectomy performed for a thymoma associated with SPS. With an
incidence of approximately 1 per million, SPS is a rare neurologic disorder, first described in 1956 by Moersch and Woltman. The main symptoms are stiffness and painful muscle spasms in the trunk and extremities. McKeon et al. reported the sex-based differences in SPS with a male to female ratio of 1:2, and the median age at the onset of symptoms was 40 years. Anti-GAD antibody is positive in 60% of patients with SPS. SPS is known to be associated with autoimmune diseases such as type 1 diabetes and Hashimoto’s disease. Paraneoplastic SPS associated with malignant tumors such as thymoma occurs in approximately 5% of SPS cases, and in addition to thymoma, breast cancer, small-cell lung cancer, colon cancer, and lymphoma are reported. Vernino and Lennon reported that only 1 of the 201 cases of thymoma had SPS. In paraneoplastic SPS with thymoma, thymectomy was considered to be an effective treatment for SPS with thymoma.

There have been 11 cases of patients who underwent surgical resection including our case (Table 1). The mean age was 53 (26–79) years; six cases (55%) comprised women. In 10 cases (91%), anti-GAD antibody was positive. It is still unclear whether thymoma or the thymus gland associated with SPS produces anti-GAD antibody. Although the consensus about the excision range has not been established yet, extended thymectomy was performed in all cases. In 10 cases (91%) including our case, symptoms improved after thymectomy, and thymectomy was thus considered to be effective. Although the anti-GAD antibody level should be correlated with symptoms, it remained high (titer >2000), and no recurrence of neurological symptom was observed in our case. The histological types according to the World Health Organization classification were AB (n = 1), B1 (n = 4), B2 (n = 2), B3 (n = 1), C (n = 1), and details unknown (n = 2). Seven cases (64%) were of type B, the most common subtype of thymoma associated with SPS. Type B is also associated with MG, supporting the notion that SPS develops via autoimmune mechanisms similar to those associated with MG. There were three cases of thymoma with SPS and MG, two cases were type B. Anti-AchR antibody was positive in two cases. Two patients developed MG after surgical resection for paraneoplastic SPS. In our case, the histological type was also type B and anti-AchR antibody remained positive after surgery. At present, the patient has not experienced recurrence for over 44 months after surgery.

**Conclusion**

Surgical treatment would be effective for patients with SPS accompanied by thymoma.
## Table 1 Case of surgically resected thymoma-related Stiff-person syndrome

| Case | Source | Age/sex | Antibodies | Response to Pathology | Postoperative | SPS recurrence | Clinical course |
|------|--------|---------|-------------|-----------------------|---------------|----------------|-----------------|
| 1    | Nicholas\(^6\) | 55/M | - | N.A. | Well | B2 | - | + | IVIG | SPS→thymectomy→MG |
| 2    | Hagiwara\(^7\) | 40/F | + | - | Well | B1 | Radiotherapy | - | - | - |
| 3    | Thomas\(^8\) | 45/M | + | N.A. | Well | N.A. | - | - | - | SPS→thymectomy→MG |
| 4    | Tanaka\(^2\) | 57/F | + | - | Well | B1 | - | + | IVIG |
| 5    | Iwata\(^9\) | 79/F | + | N.A. | Well | AB | IVIG | + | IVIG, PLEX |
| 6    | Essalmi\(^10\) | 51/M | + | + | Well | B1 | Steroid | - | - | - |
| 7    | Dupond\(^11\) | 53/M | + | + | N.A. | Well | N.A. | Steroid, IVIG, MM | + | Riuximab |
| 8    | Aghajanzadeh\(^12\) | 32/M | + | N.A. | N.A. | Well | C | - | - | - |
| 9    | Kobayashi\(^1\) | 68/F | + | N.A. | Well | B1 | Steroid | + (with recurrence thymoma) | Surgical resection | - |
| 10   | Morise\(^3\) | 72/F | + | - | Poor | B2 | PLEX | + | + |
| 11   | Our case \(^13\) | 26/F | + | N.A. | Well | B3 | - | - | - | - |

AchR: anti-acetylcholine receptor; GAD: glutamic acid decarboxylase; IVIG: intravenous immunoglobulin; N.A.: not available; MM: mycophenolate mofetil; MG: myasthenia gravis; PLEX: plasma exchange; SPS: Stiff-person syndrome
Disclosure Statement

No disclosures to report.

References

1) Kobayashi R, Kaji M, Horiuchi S, et al. Recurrent thymoma with stiff-person syndrome and pure red blood cell aplasia. Ann Thorac Surg 2014; 97: 1802–4.
2) Tanaka H, Matsumura A, Okumura M, et al. Stiff man syndrome with thymoma. Ann Thorac Surg 2005; 80: 739–41.
3) Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 2004; 10: 7270–5.
4) Siddiqui MZ, Tohid H, Brown R, et al. The stiff people: two rare cases of stiff-person syndrome. Cureus 2017; 9: e1602.
5) McKeon A, Robinson MT, McEvoy KM, et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol 2012; 69: 230–8.
6) Nicholas AP, Chatterjee A, Arnold MM, et al. Stiff-person’s syndrome associated with thymoma and subsequent myasthenia gravis. Muscle Nerve 1997; 20: 493–8
7) Hagiwara H, Enomoto-Nakatani S, Sakai K, et al. Stiff-person syndrome associated with invasive thymoma: a case report. J Neurol Sci 2001; 193: 59–62.
8) Thomas S, Critchley P, Lawden M, et al. Stiff person syndrome with eye movement abnormality, myasthenia gravis, and thymoma. J Neurol Neurosurg Psychiatry 2005; 76: 141–2.
9) Iwata T, Inoue K, Mizuguchi S, et al. Thymectomy for paraneoplastic stiff-person syndrome associated with invasive thymoma. J Thorac Cardiovasc Surg 2006; 132: 196–7.
10) Essalmi L, Meaux-Ruault N, Hafsaoui C, et al. Stiff person syndrome associated with thymoma. Efficacy of thymectomy. Rev Med Interne 2007; 28: 627–30.
11) Dupond JL, Essalim L, Gil H, et al. Rituximab treatment of stiff-person syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis. J Clin Neurosci 2010; 17: 389–91.
12) Aghajanzadeh M, Alavi A, Aghajanzadeh G, et al. Stiff man syndrome with invasive thymic carcinoma. Arch Iran Med 2013; 16: 195–6.
13) Morise S, Nakamura M, Morita JI, et al. Thymoma-associated progressive encephalomyelitis with rigidity and myoclonus (PERM) with myasthenia gravis. Intern Med 2017; 56: 1733–7.
14) Iizuka T, Leite MI, Lang B, et al. Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations. J Neurol 2012; 259: 1566–73.